Janka, E.A.; Szabó, I.L.; Kollár, S.; Toka-Farkas, T.; Ványai, B.; Várvölgyi, T.; Kapitány, A.; Shabu, H.; Szegedi, A.; Emri, G.
Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors. Cancers 2024, 16, 2981.
https://doi.org/10.3390/cancers16172981
AMA Style
Janka EA, Szabó IL, Kollár S, Toka-Farkas T, Ványai B, Várvölgyi T, Kapitány A, Shabu H, Szegedi A, Emri G.
Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors. Cancers. 2024; 16(17):2981.
https://doi.org/10.3390/cancers16172981
Chicago/Turabian Style
Janka, Eszter Anna, Imre Lőrinc Szabó, Sándor Kollár, Tünde Toka-Farkas, Beatrix Ványai, Tünde Várvölgyi, Anikó Kapitány, Hibah Shabu, Andrea Szegedi, and Gabriella Emri.
2024. "Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors" Cancers 16, no. 17: 2981.
https://doi.org/10.3390/cancers16172981
APA Style
Janka, E. A., Szabó, I. L., Kollár, S., Toka-Farkas, T., Ványai, B., Várvölgyi, T., Kapitány, A., Shabu, H., Szegedi, A., & Emri, G.
(2024). Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors. Cancers, 16(17), 2981.
https://doi.org/10.3390/cancers16172981
